|
" Supplementation of Omega-3 Fatty Acid in Women During Pregnancy: "
Su, Jessica
Gordon-Elliott, Janna
| Document Type
|
:
|
Latin Dissertation
|
| Language of Document
|
:
|
English
|
| Record Number
|
:
|
1114234
|
| Doc. No
|
:
|
TLpq2404679938
|
| Main Entry
|
:
|
Gordon-Elliott, Janna
|
|
|
:
|
Su, Jessica
|
| Title & Author
|
:
|
Supplementation of Omega-3 Fatty Acid in Women During Pregnancy:\ Su, JessicaGordon-Elliott, Janna
|
| College
|
:
|
Weill Medical College of Cornell University
|
| Date
|
:
|
2020
|
| student score
|
:
|
2020
|
| Degree
|
:
|
M.S.
|
| Page No
|
:
|
47
|
| Abstract
|
:
|
Problem: Postpartum depression (PPD) is one of the most common complications of childbirth and is a concerning major public health issue. PPD is associated with numerous adverse outcomes of the women and also the offspring and the family. If left untreated, PPD can affect the mental health of the women and also the development of the offspring. Purpose: The goal of this study is to investigate if supplementing omega-3 fatty acid to pregnant women during pregnancy can reduce the risk of developing PPD. Research Questions: Does supplementation of omega-3 fatty acid to women during pregnancy help reduce the risk of developing PPD? Methods: A randomized, double-blinded, placebo controlled clinical trial is proposed. Women who are between the ages of 18-45, in less than 12 weeks of gestation of a singleton pregnancy, with no other births in the previous two years, no chronic diseases or other psychiatric history, no current or history of major depressive disorder (MDD) and PPD, no family history of PPD, and no current substance abuse will be eligible for this study. Women who are taking antidepressants and/ or omega-3 fatty acid supplements, receiving psychotherapy, and who have a PHQ-9 score of five and above at baseline during screening will be excluded from the study. Research subjects will be recruited from Women, Infant, and Children (WIC) offices in the New York metropolitan area that are affiliated with New York Presbyterian Hospitals. Participants will be randomly assigned to 2 groups that will receive: 1) omega-3 FAs supplements containing a total of 830 mg omega-3 FAs that includes DHA/EPA (480 mg/205 mg) or 2) placebo (corn oil) from 14 weeks of gestation until 24 weeks after childbirth. Serum n-3 levels will be sampled and analyzed every 12 weeks. Symptoms of depression will be assessed prior to delivery and every 4 weeks after childbirth until 12 months by using a self-report scale- the Patient Health Questionnaire-Nine Item (PHQ-9). Outcomes: Participants will be followed for depression symptoms and possible diagnosis of PPD until 12 months after childbirth Benefit: Supplementation of omega-3 fatty acid to women during early pregnancy and early postpartum period may reduce the risk of developing PPD.
|
| Subject
|
:
|
Medicine
|
|
|
:
|
Nutrition
|
|
|
:
|
Omega-3 fatty acid
|
|
|
:
|
Postpartum depression
|
|
|
:
|
Pregnancy
|
| |